title: Pharmacometric Analyses to Support Early Development Decisions for LY2878735: A Novel Serotonin Norepinephrine Reuptake Inhibitor.
abstract: LY2878735 is a novel dual serotonin (5-hydroxytryptamine (5-HT)) and norepinephrine (NE) reuptake inhibitor (SNRI) in development for chronic pain indications. In vitro profile suggests a more balanced profile as compared with other SNRI's, which is expected to confer superior clinical efficacy. LY2878735 is metabolized partly by the genetically polymorphic cytochrome P450 (CYP) 2D6 pathway, raising pharmacokinetic (PK) variability concerns. Phase 1 PK and biomarker data were analyzed by pharmacometric methods to characterize the balance between dual-target engagement and adverse effects on heart rate (HR) and blood pressure (BP). A narrow range of plasma LY2878735 levels was associated with an acceptable balance. As compared with poor metabolizers (PM), CYP2D6 extensive metabolizers (EM) have 21- and threefold higher clearance and distribution volume, respectively. Even with a CYP2D6-based dosing paradigm, a superior therapeutic index comparable to duloxetine, a widely used SNRI, was not achievable and LY2878735 development was thus terminated. Model-based approach effectively synthesizes PK-pharmacodynamic (PD) relationships, enabling efficient early development decisions.CPT: Pharmacometrics & Systems Pharmacology (2013) 2, e66; doi:10.1038/psp.2013.43; published online 21 August 2013.
authors: Chorus, Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, Indiana, USA.
authors: E
authors: E
authors: Raddad
authors: M R
authors: MR
authors: Melhem
authors: J S
authors: JS
authors: Sloan-Lancaster
authors: J W
authors: JW
authors: Miller
authors: S A
authors: SA
authors: Van Wart
authors: C M
authors: CM
authors: Rubino
references: J Clin Psychiatry. 1998;59 Suppl 14:4-7
references: 9818623
references: AAPS J. 2005 Oct 07;7(3):E544-59
references: 16353932
references: AAPS J. 2005 Oct 07;7(3):E503-12
references: 16353928
references: Curr Med Res Opin. 2011 Jul;27(7):1303-13
references: 21561393
references: J Pharmacokinet Pharmacodyn. 2008 Apr;35(2):185-202
references: 18197467
references: Clin Pharmacol Ther. 2007 Feb;81(2):213-21
references: 17259946
references: Biol Psychiatry. 2004 Feb 1;55(3):320-2
references: 14744476
references: Clin Pharmacokinet. 2009;48(3):189-97
references: 19385712
references: Clin Pharmacol Ther. 2009 Jul;86(1):105-8
references: 19458614
references: Neuropharmacology. 2003 Dec;45(7):935-44
references: 14573386
references: Ann Clin Psychiatry. 1993 Sep;5(3):199-207
references: 8281243
references: Pharmacogenetics. 2000 Apr;10(3):187-216
references: 10803676
references: Clin Pharmacokinet. 2001;40(12):883-92
references: 11735607
references: CNS Spectr. 2005 Sep;10(9):732-47
references: 16142213
references: Psychopharmacology (Berl). 2006 Apr;185(3):395-9
references: 16506079
references: Biol Psychiatry. 1999 Nov 1;46(9):1301-8
references: 10560035
references: Eur J Pharm Sci. 2001 May;13(2):115-22
references: 11297895
references: J Clin Pharmacol. 2008 Feb;48(2):146-56
references: 18199891
references: Life Sci. 1995;57(5):411-41
references: 7623609
references: Clin Pharmacokinet. 2011 Oct;50(10):627-35
references: 21895036
references: Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):23-37
references: 14618296
references: Clin Pharmacokinet. 2011 May;50(5):281-94
references: 21366359